Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 2
1(25.0%)
Phase 1
1(25.0%)
4Total
N/A(2)
Phase 2(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03863730Not ApplicableActive Not Recruiting

Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota

Role: collaborator

NCT05475314Not ApplicableCompleted

Effect of Postbiotic Product on Colonic Barriers in IBS

Role: lead

NCT01193894Phase 2Completed

Trial on Profermin and Fresubin in Ulcerative Colitis

Role: lead

NCT01245465Phase 1Completed

Profermin® in Active Ulcerative Colitis

Role: lead

All 4 trials loaded